ASH 2022 | Pooled fecal allogeneic microbiotherapy for GI-aGvHD: results from early access program in France

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, reports results from 81 patients diagnosed with steroid-refractory (SR) or dependent (SD) gastrointestinal acute graft-versus-host disease (GI-aGvHD) treated with the pooled allogeneic microbiotherapy MaaT013 as part of the Early Access Program (EAP) in France. Overall, EAP clinical data showed that MaaT013 was safe and effective for the treatment of SR/SD-GI-aGvHD, especially in patients having previously received ruxolitinib, with the overall survival (OS) being 51% at 6 months and 39% at 12 months. Prof. Mohty expects to further confirm these results in an ongoing Phase III study (NCT04769895) in ruxolitinib-refractory patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.